Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 182

1.

Risk factors and survival by HPV-16 E6 and E7 antibody status in human papillomavirus positive head and neck cancer.

Smith EM, Pawlita M, Rubenstein LM, Haugen TH, Hamsikova E, Turek LP.

Int J Cancer. 2010 Jul 1;127(1):111-7. doi: 10.1002/ijc.25015.

2.

Human papillomavirus seropositivity and risks of head and neck cancer.

Smith EM, Ritchie JM, Pawlita M, Rubenstein LM, Haugen TH, Turek LP, Hamsikova E.

Int J Cancer. 2007 Feb 15;120(4):825-32.

3.

Does pretreatment seropositivity to human papillomavirus have prognostic significance for head and neck cancers?

Smith EM, Rubenstein LM, Ritchie JM, Lee JH, Haugen TH, Hamsikova E, Turek LP.

Cancer Epidemiol Biomarkers Prev. 2008 Aug;17(8):2087-96. doi: 10.1158/1055-9965.EPI-08-0054.

4.

Detection of transcriptionally active high-risk HPV in patients with head and neck squamous cell carcinoma as visualized by a novel E6/E7 mRNA in situ hybridization method.

Bishop JA, Ma XJ, Wang H, Luo Y, Illei PB, Begum S, Taube JM, Koch WM, Westra WH.

Am J Surg Pathol. 2012 Dec;36(12):1874-82. doi: 10.1097/PAS.0b013e318265fb2b.

5.

Biomarkers of HPV in head and neck squamous cell carcinoma.

Liang C, Marsit CJ, McClean MD, Nelson HH, Christensen BC, Haddad RI, Clark JR, Wein RO, Grillone GA, Houseman EA, Halec G, Waterboer T, Pawlita M, Krane JF, Kelsey KT.

Cancer Res. 2012 Oct 1;72(19):5004-13. doi: 10.1158/0008-5472.CAN-11-3277. Epub 2012 Sep 18.

6.

Markers of HPV infection and survival in patients with head and neck tumors.

Koslabova E, Hamsikova E, Salakova M, Klozar J, Foltynova E, Salkova E, Rotnaglova E, Ludvikova V, Tachezy R.

Int J Cancer. 2013 Oct 15;133(8):1832-9. doi: 10.1002/ijc.28194. Epub 2013 May 2.

7.
8.

Antibodies against oncoproteins E6 and E7 of human papillomavirus types 16 and 18 in cervical-carcinoma patients from Russia.

Zumbach K, Kisseljov F, Sacharova O, Shaichaev G, Semjonova L, Pavlova L, Pawlita M.

Int J Cancer. 2000 Feb 1;85(3):313-8.

9.

Human papillomavirus serologic follow-up response and relationship to survival in head and neck cancer: a case-comparison study.

Rubenstein LM, Smith EM, Pawlita M, Haugen TH, Hamšíková E, Turek LP.

Infect Agent Cancer. 2011 Jul 8;6:9. doi: 10.1186/1750-9378-6-9.

10.

P16INK4a expression, human papillomavirus, and survival in head and neck cancer.

Smith EM, Wang D, Kim Y, Rubenstein LM, Lee JH, Haugen TH, Turek LP.

Oral Oncol. 2008 Feb;44(2):133-42. Epub 2007 Mar 13.

PMID:
17360226
11.

HPV DNA, E6/E7 mRNA, and p16INK4a detection in head and neck cancers: a systematic review and meta-analysis.

Ndiaye C, Mena M, Alemany L, Arbyn M, Castellsagué X, Laporte L, Bosch FX, de Sanjosé S, Trottier H.

Lancet Oncol. 2014 Nov;15(12):1319-31. doi: 10.1016/S1470-2045(14)70471-1. Epub 2014 Oct 16. Erratum in: Lancet Oncol. 2015 Jun;16(6):e262.

PMID:
25439690
12.

A non-oncogenic HPV 16 E6/E7 vaccine enhances treatment of HPV expressing tumors.

Wieking BG, Vermeer DW, Spanos WC, Lee KM, Vermeer P, Lee WT, Xu Y, Gabitzsch ES, Balcaitis S, Balint JP Jr, Jones FR, Lee JH.

Cancer Gene Ther. 2012 Oct;19(10):667-74. doi: 10.1038/cgt.2012.55. Epub 2012 Aug 24.

13.

The presence of high-risk human papillomavirus (HPV) E6/E7 mRNA transcripts in a subset of sinonasal carcinomas is evidence of involvement of HPV in its etiopathogenesis.

Laco J, Sieglová K, Vošmiková H, Dundr P, Němejcová K, Michálek J, Čelakovský P, Chrobok V, Mottl R, Mottlová A, Tuček L, Slezák R, Chmelařová M, Sirák I, Vošmik M, Ryška A.

Virchows Arch. 2015 Oct;467(4):405-15. doi: 10.1007/s00428-015-1812-x. Epub 2015 Jul 31.

PMID:
26229021
15.

A novel HPV 16 L1-based chimeric virus-like particle containing E6 and E7 seroreactive epitopes permits highly specific detection of antibodies in patients with CIN 1 and HPV-16 infection.

Monroy-García A, Gómez-Lim MA, Weiss-Steider B, la Rosa GP, Hernández-Montes J, Pérez-Saldaña K, Tapia-Guerrero YS, Toledo-Guzmán ME, Santiago-Osorio E, Sanchez-Peña HI, Mora-García Mde L.

Virol J. 2011 Feb 9;8:59. doi: 10.1186/1743-422X-8-59.

16.

Human papillomavirus infections and upper aero-digestive tract cancers: the ARCAGE study.

Anantharaman D, Gheit T, Waterboer T, Abedi-Ardekani B, Carreira C, McKay-Chopin S, Gaborieau V, Marron M, Lagiou P, Ahrens W, Holcátová I, Merletti F, Kjaerheim K, Talamini R, Simonato L, Castellsague X, Macfarlane TV, Biggs AM, Thakker N, Znaor A, Thomson P, Canova C, Conway DI, Healy CM, Tommasino M, Pawlita M, Brennan P.

J Natl Cancer Inst. 2013 Apr 17;105(8):536-45. doi: 10.1093/jnci/djt053. Epub 2013 Mar 16.

17.

Human papillomavirus type 18 E6 and E7 antibodies in human sera: increased anti-E7 prevalence in cervical cancer patients.

Bleul C, Müller M, Frank R, Gausepohl H, Koldovsky U, Mgaya HN, Luande J, Pawlita M, ter Meulen J, Viscidi R, et al.

J Clin Microbiol. 1991 Aug;29(8):1579-88.

18.

Novel oligomannose liposome-DNA complex DNA vaccination efficiently evokes anti-HPV E6 and E7 CTL responses.

Mizuuchi M, Hirohashi Y, Torigoe T, Kuroda T, Yasuda K, Shimizu Y, Saito T, Sato N.

Exp Mol Pathol. 2012 Feb;92(1):185-90. doi: 10.1016/j.yexmp.2011.10.002. Epub 2011 Oct 15.

PMID:
22032938
19.

Serologic response in human papillomavirus-associated invasive cervical cancer.

Viscidi RP, Sun Y, Tsuzaki B, Bosch FX, Muñoz N, Shah KV.

Int J Cancer. 1993 Nov 11;55(5):780-4.

PMID:
8244575
20.

Demographic and risk factors in patients with head and neck tumors.

Tachezy R, Klozar J, Rubenstein L, Smith E, Saláková M, Smahelová J, Ludvíková V, Rotnáglová E, Kodet R, Hamsíková E.

J Med Virol. 2009 May;81(5):878-87. doi: 10.1002/jmv.21470.

PMID:
19319944

Supplemental Content

Support Center